HALO logo
halo search icon
Aclarion, Inc.
Aclarion, Inc.
ACON · NAS

Aclarion, Inc.

US$3.19

Price Arrow-0.01 (-0.313%)
20/05/2026 04:00:00 PM
All-CompaniesAll-ConsensusEngulfing BullishHALO AllHALO Consensus ValueHALO GrowthHammer Bearish (Realtime)
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Aclarion, Inc. Overview

ACON Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About ACON

icon

Website

Aclarion, Inc.

icon

Telephone

1.833.275.2266

icon

Address

Suite 100, 8181 Arista Place, Broomfield, CO 80021

Description

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

ACON Price Chart

Key Stats

Market Cap

US$7.88M

PE

0.00

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 2.34 - 12.03

Trade Value (12mth)

US$504,070.00

1 week

1.27%

1 month

-9.35%

YTD

-35.74%

1 year

-53.42%

All time high

586116.00

Key Fundamentals

EPS 3 yr Growth

-100.00%

EBITDA Margin

NaN%

Operating Cashflow

-$7m

Free Cash Flow Return

-103.80%

ROIC

-104.80%

Interest Coverage

0.00

Quick Ratio

14.80

Other Data

Shares Outstanding (Fully Diluted)

2m

HALO Sector

Technology

Next Company Report Date

03-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

ACON Announcements

Latest Announcements

DateAnnouncements
14 May 26
14 May 26
22 April 26
22 April 26
14 January 26

ACON Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-79,782.69-7,480.22-13.61locklocklock
EPS (Fully Diluted)
$locklocklocklock-79,782.69-7,480.22-13.61locklocklock
Growth
%locklocklocklock5590.699.8locklocklock
PE
XlocklocklocklockN/AN/AN/Alocklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Aclarion, Inc. (ACON:NAS)?
Halo FAQ
The current share price of Aclarion, Inc. (ACON:NAS) is USD$3.19.
What is the 52-week high share price for Aclarion, Inc. (ACON:NAS)?
Halo FAQ
The 52-week high share price for Aclarion, Inc. (ACON:NAS) is USD$12.03.
What is the 52-week low share price for Aclarion, Inc. (ACON:NAS)?
Halo FAQ
The 52-week low share price for Aclarion, Inc. (ACON:NAS) is USD$2.34.
What is the dividend yield for Aclarion, Inc. (ACON:NAS)?
Halo FAQ
Aclarion, Inc. (ACON:NAS) does not pay a dividend.
What was Aclarion, Inc. (ACON:NAS) last dividend payment?
Halo FAQ
Aclarion, Inc. (ACON:NAS) does not pay a dividend.
What is the franking level for Aclarion, Inc. (ACON:NAS)?
Halo FAQ
Aclarion, Inc. (ACON:NAS) has a franking level of 0.00%.
In which sector is Aclarion, Inc. (ACON:NAS) classified?
Halo FAQ
Aclarion, Inc. (ACON:NAS) is classified in the Technology.

See beyond the curve.

One solution for research, investing and portfolio management.